LSTA:NASDAQ, Lisata Therapeutics, Inc.

LSTA stock overview

Lisata Therapeutics, Inc. (LSTA:NASDAQ) closed at $0.996 on October 23, 2026, down 0.91% on the day. The stock trades 80.4% below its 52-week high of $5.07 and 3.7% above its 52-week low of $0.960. Over the past year, it lost 57.6%. Lisata Therapeutics, Inc. is part of the Health Care sector.

Key figures

Price: $0.996
Day change: -0.91%
Volume: 45,557
Average volume: 297,915
Market cap: 10M+
52-week range: $0.960 – $5.07
50-day average: $1.40
200-day average: $3.02

Price action over the past year

In 252 trading sessions since October 23, 2025, LSTA closed higher on 93 days (37%). Its best day was January 21, 2026 (+86.57%) and its worst was July 21, 2026 (-36.54%). The stock moved 10% or more in a single session 24 times. It opened at least 5% above the previous day's high 5 times.

Recent signals

Oct 23, 2026: Down 33.6% over 30 days, from $1.50 (Dips & Crashes scanner)
Oct 23, 2026: Trading sideways between $0.996 and $1.08 over 14 days (Sideways scanner)
Oct 23, 2026: Hit a new 1-Month Low of $0.996 (New Highs/Lows scanner)
Oct 14, 2026: News catalyst: Investor Update (News Catalysts scanner)
Sep 17, 2026: Spiked to $2.56 on 3M+ shares (Spikes scanner)

LSTA news

About Lisata Therapeutics, Inc.

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its current product candidates include XOWNA, HONEDRA and CLBS201.

Similar stocks

Find more stocks like LSTA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.